MedTrace Logo

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

NCT00289848 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2015-06-15

Study results available
· View outcomes & findings →

Summary

This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

sitagliptin phosphate

Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.

DRUG

Comparator: placebo

placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-03-31
Completion
2007-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289848 on ClinicalTrials.gov